CARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) -- This article contains affiliate links. If you purchase through these links, a commission…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed…
MUMBAI, India, Nov. 18, 2025 /PRNewswire/ -- Teeth may not always be the first thing that comes to mind in…
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses…
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab…
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company…
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective…
IRVING, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) – a management services organization that exclusively…